Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS

• Main Authors: Ausayakhun S., Watananikorn S., Ngamtiphakorn S., Prasitsilp J.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-20444472320&partnerID=40&md5=b16aa4282b84ec18b8998b4cdf0e0e61; http://www.ncbi.nlm.nih.gov/pubmed/15960227; http://cmuir.cmu.ac.th/handle/6653943832/1970
• Institution: Chiang Mai University

To determine the visual outcome, progression, and complications of patients with acquired immunodeficiency syndrome-related cytomegalovirus (CMV) retinitis treated with intravitreal foscarnet (2.4 mg in 0.1 ml per injection), a retrospective study was carried out in 193 patients. Induction therapy consisted of two injections a week until the lesions were inactive. Maintenance therapy consisted of one injection a week until relapse, then re-induction was instituted. In 301 treated eyes, visual acuity remained stable in 184 (61%), improved in 16 (5%), and decreased in 101 (34%). Of these, 15 retinal detachments, 13 intravitreal hemorrhages, 3 endophthalmitis, and 2 cataract occurred. Median time of first progression was 15 weeks. Involvement of the fellow eye occurred in 35% of the patients during treatment of the first eye. Intravitreal foscarnet appeared to be a useful alternative treatment for patients intolerant or unaffordable to intravenous anti-CMV drugs, but the complications of this treatment should also be considered.